ReviewDrugs2024
Therapeutic Potential of Lipoprotein(a) Inhibitors.
Review in Drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Lipoprotein(a), insulin resistance, and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease.Cardiovascular diabetology · 2026Article
- Statin treatment in routine clinical practice: Insights from the STATRIP physician survey.Atherosclerosis plus · 2026Article
- Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank.Journal of the American Heart Association · 2026Article
- Lowering of Lipoprotein(a) with Olpasiran.Cardiovascular & hematological disorders drug targets · 2026Review
- Beyond conventional therapies: Gut microbiota modulation and macromolecular drugs in the battle against cardiometabolic diseases.Journal of pharmaceutical analysis · 2026Review
- Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a).Cardiovascular & hematological disorders drug targets · 2026Review
- Cardiovascular Risk and Its Presentation in Chronic Kidney Disease.Journal of clinical medicine · 2025Review
- Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications.Journal of clinical medicine · 2025Review
- Targeting lipoprotein(a): Pharmacotherapy in focus.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- The influence of lipoprotein(a) on aortic valve calcification in patients undergoing transcatheter aortic valve replacement.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study.American journal of preventive cardiology · 2025Article
- 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.Archives of medical science : AMS · 2025Article
- Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies.Frontiers in molecular biosciences · 2025Review
- Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.International journal of molecular sciences · 2024Article
- Lipoprotein(a) and the atherosclerotic burden - Should we wait for clinical trial evidence before taking action?Atherosclerosis plus · 2024Review
- Coronary Plaque Regression and Fractional Flow Reserve Improvement in a Chronic Coronary Syndrome Case: Early Optimal Medical Therapy and Fractional Flow Reserve-Computed Tomography Follow-Up Strategy.Diseases (Basel, Switzerland) · 2024Article
- Lipoprotein(a) and cardiovascular disease.The Biochemical journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence has implicated lipoprotein(a) [Lp(a)] in the causality of atherosclerosis and calcific aortic stenosis. This has stimulated immense interest in developing novel approaches to integrating Lp(a) into the setting of cardiovascular prevention. Current guidelines advocate universal measurement of Lp(a) levels, with the potential to influence cardiovascular risk assessment and triage of higher-risk patients to use of more intensive preventive therapies. In parallel, considerable activity has been undertaken to develop novel therapeutics with the potential to achieve selective and substantial reductions in Lp(a) levels. Early studies of antisense oligonucleotides (e.g., mipomersen, pelacarsen), RNA interference (e.g., olpasiran, zerlasiran, lepodisiran) and small molecule inhibitors (e.g., muvalaplin) have demonstrated effective Lp(a) lowering and good tolerability. These agents are moving forward in clinical development, in order to determine whether Lp(a) lowering reduces cardiovascular risk. The results of these studies have the potential to transform our approach to the prevention of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.